Catheter Precision, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US74933X3026
USD
2.42
0.04 (1.68%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

38.47 k

Shareholding (Mar 2025)

FII

0.57%

Held by 4 FIIs

DII

98.75%

Held by 1 DIIs

Promoter

0.00%

How big is Catheter Precision, Inc.?

22-Jun-2025

As of Jun 18, Catheter Precision, Inc. has a market capitalization of 4.19 million, with net sales of 0.48 million and a net profit of -18.01 million over the latest four quarters. The company reported shareholder's funds of 11.76 million and total assets of 27.77 million as of Dec 24.

Market Cap: As of Jun 18, Catheter Precision, Inc. has a market capitalization of 4.19 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Catheter Precision, Inc. reported net sales of 0.48 million and a net profit of -18.01 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company reported shareholder's funds of 11.76 million and total assets of 27.77 million.

Read More

What does Catheter Precision, Inc. do?

22-Jun-2025

Catheter Precision, Inc. is a micro-cap medical device company that develops excimer lasers for treating dermatological and vascular diseases. As of March 2025, it reported net sales of $0 million and a net loss of $4 million, with a market cap of $4.19 million.

Overview: <BR>Catheter Precision, Inc. is a medical device company focused on commercializing excimer lasers for the treatment of dermatological and vascular diseases, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -4 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 4.19 Million (Micro Cap)<BR><BR>Key Metrics: <BR>Debt Equity: 1.47 <BR>Return on Equity: -184.16% <BR>Price to Book: 0.53<BR><BR>Contact Details: <BR>Address: 2070 Las Palmas Dr, Carlsbad CA: 92011-1518 <BR>Tel: 1 760 8041648 <BR>Website: https://www.ramed.com/

Read More

Is Catheter Precision, Inc. overvalued or undervalued?

25-Jun-2025

As of August 15, 2022, Catheter Precision, Inc. is considered overvalued with a valuation grade of "does not qualify" due to negative earnings, poor performance metrics, and a one-year stock return of -95.54%, significantly underperforming compared to its peers and the S&P 500.

As of 15 August 2022, the valuation grade for Catheter Precision, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial health. The company is currently deemed overvalued, primarily due to its negative earnings and poor performance metrics. The Price to Book Value stands at 0.29, while the EV to EBITDA is at -1.40, and the ROCE is a concerning -61.81%. <BR><BR>In comparison to its peers, Catheter Precision's valuation ratios are notably worse; for instance, Cardio Diagnostics Holdings, Inc. has an EV to EBITDA of 0.5065, while Vivos Therapeutics, Inc. shows an EV to EBITDA of -1.0143. The stark contrast in these ratios highlights Catheter Precision's relative weakness in the market. Additionally, the company's stock has underperformed significantly, with a one-year return of -95.54% compared to a 10.26% return for the S&P 500, further reinforcing the notion that it is overvalued at its current price of $0.27.

Read More

Is Catheter Precision, Inc. technically bullish or bearish?

20-Sep-2025

As of September 2, 2025, Catheter Precision, Inc. shows a mildly bullish trend overall, but significant bearish indicators and underperformance compared to the S&P 500 suggest caution.

As of 2 September 2025, the technical trend for Catheter Precision, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bullish, while the monthly MACD is also mildly bullish. The monthly RSI indicates a bullish stance, but the weekly RSI shows no signal. However, the daily moving averages are bearish, and both the weekly and monthly KST and Dow Theory are bearish. The Bollinger Bands reflect a mildly bearish stance on both weekly and monthly time frames. <BR><BR>In terms of performance, the stock has significantly underperformed compared to the S&P 500, with a year-to-date return of -68.61% versus the S&P 500's 12.22%, and a one-year return of -68.4% compared to 17.14% for the index. Overall, the current technical stance is mildly bullish but with considerable bearish indicators present, suggesting caution.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

1.95

stock-summary
Return on Equity

-203.49%

stock-summary
Price to Book

0.45

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Jun 2025)
Net Profit:
-5 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-4.72%
0%
-4.72%
6 Months
-36.7%
0%
-36.7%
1 Year
-66.22%
0%
-66.22%
2 Years
-97.37%
0%
-97.37%
3 Years
-99.72%
0%
-99.72%
4 Years
-99.99%
0%
-99.99%
5 Years
-100.0%
0%
-100.0%

Catheter Precision, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-35.96%
EBIT Growth (5y)
11.60%
EBIT to Interest (avg)
-22.51
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
1.47
Sales to Capital Employed (avg)
0.02
Tax Ratio
15.50%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
8.32%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
0.29
EV to EBIT
-1.16
EV to EBITDA
-1.40
EV to Capital Employed
0.71
EV to Sales
13.96
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-61.81%
ROE (Latest)
-184.16%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
No Trend
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 1 Schemes (0.68%)

Foreign Institutions

Held by 4 Foreign Institutions (0.57%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 100.00% vs 0.00% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -37.50% vs 28.57% in Mar 2025",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.10",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.30",
          "val2": "-2.90",
          "chgp": "20.69%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-3.50",
          "val2": "-1.30",
          "chgp": "-169.23%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-5.50",
          "val2": "-4.00",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-13,386.80%",
          "val2": "-24,167.80%",
          "chgp": "1,078.10%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 76.49% vs -162.45% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.10",
          "val2": "-15.10",
          "chgp": "39.74%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.10",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-2.20",
          "val2": "-53.70",
          "chgp": "95.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-16.60",
          "val2": "-70.60",
          "chgp": "76.49%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-26,769.00%",
          "val2": "-38,880.10%",
          "chgp": "1,211.11%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.20
0.10
100.00%
Operating Profit (PBDIT) excl Other Income
-2.30
-2.90
20.69%
Interest
0.10
0.00
Exceptional Items
-3.50
-1.30
-169.23%
Consolidate Net Profit
-5.50
-4.00
-37.50%
Operating Profit Margin (Excl OI)
-13,386.80%
-24,167.80%
1,078.10%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Jun 2025 is 100.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -37.50% vs 28.57% in Mar 2025

Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.40
0.40
Operating Profit (PBDIT) excl Other Income
-9.10
-15.10
39.74%
Interest
0.10
0.00
Exceptional Items
-2.20
-53.70
95.90%
Consolidate Net Profit
-16.60
-70.60
76.49%
Operating Profit Margin (Excl OI)
-26,769.00%
-38,880.10%
1,211.11%
USD in Million.
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 76.49% vs -162.45% in Dec 2023

stock-summaryCompany CV
About Catheter Precision, Inc. stock-summary
stock-summary
Catheter Precision, Inc.
Pharmaceuticals & Biotechnology
Ra Medical Systems, Inc. is a medical device company. The Company is focused on commercializing excimer lasers for use in the treatment of dermatological and vascular diseases. It develops, manufactures and markets medical devices targeting the dermatology and vascular specialties. It operates through two segments: the vascular segment and the dermatology segment. The Company’s laser technology is used for the treatment of psoriasis, vitiligo, atopic dermatitis, leukoderma, and peripheral artery disease (PAD). Its Destruction of Arteriosclerotic Blockages by Laser Radiation Ablation (DABRA) is an excimer laser and disposable catheter system treatment of vascular blockages resulting from lower extremity vascular disease. Pharos is its excimer laser device that emits highly concentrated ultraviolet light and is used as a tool in the treatment of dermatological skin disorders.
Company Coordinates stock-summary
Company Details
2070 Las Palmas Dr , Carlsbad CA : 92011-1518
stock-summary
Tel: 1 760 8041648
stock-summary
Registrar Details